Augmentation of oncology immunotherapies by pterostilbene containing compositions
Inventors
Dixon, Timothy G. • Berg, Gerry B. • Graham, Robert F. • Kesari, Santosh • Ichim, Thomas
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9682047-B2
Publication Date
2017-06-20
Expiration Date
Abstract
Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.
Core Innovation
The disclosed subject matter relates to pterostilbene-containing compositions used to augment anti-tumor immunity. The approach de-represses tumor-targeting immune responses and enhances ADCC in the context of anti-tumor immune activity.
The document connects these effects to immune-modulating mechanisms including increased IFN-gamma/Th1 responses and suppression of regulatory T cells (Tregs). It further describes mitigation of oxidative stress to prevent CD3-/TCR zeta downregulation and modulation of suppressive immune cell populations including MDSCs, type 2 macrophages, and activated neutrophils.
The disclosure includes efficacy in antigen-specific immunotherapies and IL-2 therapy, including references to trastuzumab and other monoclonal antibodies. It describes synergistic inhibition of B16 melanoma when combining IL-2 with pterostilbene and reports increased mitogen-induced IFN-gamma production.
Claims Coverage
The provided content includes one independent claim covering one inventive feature set: a method of treating cancer by administering a composition comprising pterostilbene and IL-2.
Treating cancer with pterostilbene and IL-2
Selecting a subject having a cancerous tumor and administering to the subject a composition comprising an effective amount of pterostilbene and IL-2.
The claim coverage centers on cancer treatment by administering a composition containing pterostilbene together with IL-2.
Stated Advantages
Augments anti-tumor immunity.
De-represses tumor-targeting immune responses.
Enhances ADCC.
Improves efficacy of antigen-specific immunotherapies, including trastuzumab and other monoclonal antibodies, and IL-2 therapy.
Increases IFN-gamma/Th1 responses.
Suppresses regulatory T cells (Tregs).
Mitigates oxidative stress to prevent CD3-/TCR zeta downregulation.
Modulates suppressive immune cell populations including MDSCs, type 2 macrophages, and activated neutrophils.
Documented Applications
Synergistic inhibition of B16 melanoma using IL-2 plus pterostilbene, with increased mitogen-induced IFN-gamma production.
Use with antigen-specific immunotherapies, including trastuzumab and other monoclonal antibodies, to improve efficacy.
Use in combination with IL-2 therapy to augment anti-tumor immunity.
Interested in licensing this patent?